Bull&Bear | Chinese Stocks and Gold Prices Surge Amid Market Rally

On the topic of rising stocks:

Dogness (DOGZ) rose by 32.99%, marking a three-day closing streak with a cumulative increase of 38.76% over the past three days. Late-night surge! The Chinese Yuan and A50 index rallied, popular Chinese concept stocks moved higher across the board, and gold and silver prices soared.

CorMedix (CRMD) rose by 30.16%, marking a two-day closing streak with a cumulative increase of 35.16% over the past two days. CorMedix's DefenCath has driven growth, with impressive early sales figures and a strong buy outlook, showcasing positive prospects.

SIGA Technologies (SIGA) rose by 26.94%, marking a three-day closing streak with a cumulative increase of 37.74% over the past three days. The World Health Organization has indicated that an expert committee will propose the adoption of the Mpox vaccine under the Emergency Use Listing by mid-September.

Clover Health (CLOV) rose by 25.50%, marking a five-day closing streak with a cumulative increase of 50.75% over the past five days. Following the purchase of shares by Director Vivek Garipalli, Clover Health Investments’ stock price has seen a significant uptick.

Nano Nuclear (NNE) rose by 19.55%. The company has appointed former Congressman and District Attorney Dan Donovan as the Chairman of its Executive Advisory Board, responsible for market intelligence.

On the topic of falling stocks:

Verrica (VRCA) fell by 40.80%. Analysts at Needham maintained a buy rating on Verrica Pharmaceuticals but lowered their target price to $12.

Ouster (OUST) fell by 27.67%, marking a two-day decline with a cumulative decrease of 27.93% over the past two days. Western Capital has revised its price target for Ouster's stock from $17.00 per share to $13.00 per share.

European Wax Center (EWCZ) fell by 26.98%. Piper Jaffray has adjusted the target price for European Wax Center from $12 to $8.

Ibotta (IBTA) fell by 26.69%. Following the Q2 results, analysts at Raymond James have cut their forecasts for Ibotta. They maintained an outperform rating but lowered the target price to $75. Due to poor performance, other firms have also decreased their price targets. Ibotta's operating inefficiencies led to more significant than expected losses in Q2, causing its stock to drop by 19%.

Puma Biotechnology (PBYI) fell by 24.79%. A federal judge's dismissal of a patent application supporting Puma Biotechnology's breast cancer drug has resulted in a post-market stock price decline.